mir medical international research s.r.l

Innovation in Spirometry, Oximetry and MedTech solutions

All of humanity is today immersed in a global pandemic. Since the beginning of the COVID–19 emergency, our collective future has been rapidly accelerated, and we must respond with a strong capacity for action to reinvent the many processes to which we had become accustomed and which today have suddenly become obsolete.

Smart working is quickly becoming the rule, rather than the exception, in small and large companies alike. Simultaneously, healthcare is also rapidly becoming Smart: we rarely attend doctors’ offices and avoid trips to the hospital whenever possible.

Nevertheless, we need now, more than ever, greater accessibility to tools that allow us to personally assess our state of health and, in particular, the health of our lungs and overall respiratory function. For more than 25 years, we have been internationally recognized for our numerous innovations and advancements. The products we are designing today will be more exciting and more innovative than anything you have seen before.

Projects and Partnerships

After recovering from a COVID–19 infection, the lungs are still at increased risk for at least 6 months and 30% of recovered patients may ultimately develop future chronic respiratory problems. In this worrying scenario, portable MIR devices have become invaluable strategic tools that have been rapidly integrated into multiple countries’ comprehensive health systems to help manage this emergency.

Pneumological teams responsible for studying the ever–growing number of patients undergoing rehabilitation, respiratory physiotherapy and clinical monitoring have found our products and solutions to be greatly helpful.

A Global Company

MIR – Medical International Research is a global medical device leader in Spirometry, Oximetry and MedTech solutions.

Founded in 1993, MIR today is present in more than 100 countries worldwide, making its most innovative technology available to healthcare professionals and their patients in the pneumology sector by pairing a series of new, reliable, and ready–to–use smartphone–compatible Smart devices with its professional line of products to help facilitate more comprehensive personal health monitoring.

Our products offer a competitive advantage because directly align with the rapidly growing global mega–trend of new public–private and home healthcare models.

Request More Information

We’re excited to share more information with you about MIR! Please fill out the below form to learn more.

Innovation in Spirometry, Oximetry and MedTech solutions

MIR – Medical International Research is a global medical device leader in Spirometry, Oximetry and MedTech solutions.

Founded in 1993 , MIR today is present in more than 100 countries worldwide , making its most innovative technology available to healthcare professionals and their patients in the pneumology sector by pairing a series of new, reliable, and ready–to–use smartphone–compatible Smart devices with its professional line of products to help facilitate more comprehensive personal health monitoring .

For more than 25 years, we have been internationally recognized for our numerous innovations and advancements. The products we are designing today, will be more exciting and more innovative than anything you have seen before.

Our last innovation is Cardionica : the first personal EKG you can use in stand-alone mode and via Bluetooth® directly from your Smartphone

Certificates

MIR solutions for HealthCare are CE Marked and FDA cleared. A wide range of local import certifications have also been accomplished, making MIR products available in your country. MIR is internationally recognized for the uniqueness of our patented products.

• MDD CE Certificate
• Import License - Serbia

Portable EKG Cardionica© is the new outbreaking device for atrial fibrillation detection developed thanks to the collaboration between MIR and Cardionica.

The partnership with cardionica.

Founded in September 2014 as a spin-off company of the Italian National Institute of Health , Cardionica was formed as a developer of innovative technologies for telemedicine and m-health. Building on its experience with researches in the biomedical engineering and ICT sectors, Cardionica provides solutions, prototyping and consulting services to companies in the health sector.

With a commitment to technical excellence and a broad portfolio of practical scalable solutions, Cardionica is working to create enabling technologies for the next-generation telemedicine and m-health systems .

Thank you for contacting us

We will get back to you as soon as possible.

Subscription successful

Thank you for signing up to our newsletter. Periodically you will receive communications on Cardionica, we will keep you updated on all the news and events.

Sorry, an error has occurred.

Please try again later.

• {{>productsMenu}} Products
• {{>trendsMenu}} News & Trends
• News & Trends
• Exhibitions

MIR - Medical International Research

A Made in Italy story worth to be told: with your breath for over 30 years.

At MIR Medical International Research, we develop premium medical devices, including spirometers and oximeters for professional and personal use to manage and prevent respiratory conditions.

Founded in Rome in 1993, MIR has been an ambitious dream since its inception: to promote early diagnosis and monitoring of respiratory diseases all over the world.

With 3 direct branches in North America, France, and Brazil, and a robust distribution network, our products are available in over 100 countries.

The multiple certifications obtained over time (FDA, NMPA, ANVISA, COFEPRIS, Health Canada, among others) and 8 international patents contribute to making MIR products not only accessible worldwide but also compliant with the latest guidelines and highest quality standards.

With a comprehensive and integrated portfolio that combines professional and personal-use devices, MIR extends the monitoring of respiratory functions beyond clinical settings, promoting research and telemedicine for home monitoring and proactive lung health management.

MIR is not just a provider of high-quality instruments, but your ally in the fight against respiratory diseases.

Together, we chart new horizons for better health.

MIR is a globally breathing company, born in Rome over 30 years ago with the dream to export the excellence of Made in Italy worldwide.

Guided by innovation, quality, responsibility, trust in new generations, and sustainability, we translate industry challenges into opportunities for our partners and the community.

Innovation and Technology We promote innovation and invest our resources daily in Research & Development. As a visionary leader in Spirometry, Oximetry, and Telemedicine, we adapt to current and future challenges to ensure medical solutions that keep pace with modern needs for accessible health care for all.

Professional Development and Training Our mantra for 2024 is: 3 generations, 30 years of MIR. This year marks the anniversary of our company, which has had the honor of nurturing many Talents since its foundation in 1993. In our work environment, 3 generations coexist. We believe in and invest in young people, guiding them in their professional and personal growth. Our diverse Team is a generator of ideas, built on solid foundations and always a step ahead in the future of technology.

Sustainability and Social Impact Every day, we choose tomorrow. Our company is a small ecosystem where every resource is integral and fundamental. For the same reason, we take care of the planet we live on, contributing with everyday choices to create a more sustainable world. On December 5, 2022, the first MIR forest was born, along with the project "Let the Planet Take a Breath": for every country that is part of our distribution network, we made the planting of a tree possible. What are now small plants will be trees capable of bearing fruit, providing shade, absorbing CO2, emitting oxygen, holding the soil with their roots, promoting biodiversity, and providing income opportunities and empowering local communities.

Responsibility For MIR, responsibility guides our entrepreneurial choices, determining our behavior towards our branches, partners, distributors, end users, employees, and service providers. In our company, we have the responsibility to ensure equity, equal opportunities, and inclusion. We are responsible to all those who use our devices. Therefore, we commit every day to providing accessible medical solutions that meet the highest quality standards and to promoting prevention and health awareness activities in our territory.

• Manufacturer account
• Buyer account
• Our services
• Newsletter subscription
• About VirtualExpo Group

WHY CHOOSE THE SMART ONE SPIROMETERS?

– better quality of life.

You can go without eating, drinking or sleeping for some time, but you cannot stop breathing. Healthy lungs ensure the best possible quality of life.

– Physical well-being

Monitoring your lungs is extremely important. A drop in your blood oxygen levels can indicate significant changes in your health or fitness.

– Increased Performance

Being physically active has many benefits, including strengthening your heart and improving pulmonary function. Consistently monitoring your physical activity can help increase performance during sport or rehabilitation

– Simple monitoring

Monitoring blood saturation, keeping control of any lung conditions such as Asthma and Cystic Fibrosis, or simply monitoring your lung function is critically important. If there is an easy way to do this, even better.

MIR Spirometers and oximeters for personal care

Wellness begins with a breath.

Breathing well is essential for a good quality of life. Monitoring how you breathe and the oxygen level in your blood is key for healthy living. Sharing results with your doctor has never been easier or faster.

CERTIFIED MADE IN ITALY QUALITY

Ensured by mir.

Medical device with CE marking, deductible from healthcare costs

Constant tracking

Spirometry and oximetry.

Peak Flow, FEV1, SpO2% and BPM

Easy to use

For tracking and sharing.

Test results in real time on your smartphone via Bluetooth

Suitable for everyone

From 5 to 93 years old.

Every member of the family can use it

Device, turbine and Mir Smart One™ APP

Our products

Connect your device to MIR Smart One app via Bluetooth and track your lung health daily directly from your Smartphone or Tablet.

You can view your test results in real time, save them, and share them with anyone who needs them.

The App is available for iOS and Android

• Smart One Oxi

Satisfied customers

“I have a very serious lung disease and I need to know how well or bad my lungs are with regards to receiving and expelling oygen!”

“Have been experiencing shortness of breath and breathing issues for the first time in my life, as a Long Covid patient. I have been debating going back to the pulmonologist, but the results of my FEV1 on this handy spirometer confirm that I need to do so. It works PERFECTLY. It set up in less than a minute. You could pull this thing out of the box, download the app, and give your first reading in less than a minute if you wanted to. [...] Amazing product worth more than I paid for it! ”

Loyal NY Mets Fan

“This product records results to your phone date, time, heart rate etc. Especially useful for showing to your Doctor. It is accurate as a recent trip to A&E confirmed this to be the case.”

Amazon Customer

“Very accurate. I tested it against 2 mechanical peak flow meters. Connects easily with your iphone and gives you a lot of data and metrics that you can save and email. This is professional medical equipment that works well. When you blow into the tube your breath spins a propeller. Optical sensors in the unit measure the rpm and duration to determine you measurements. Very ingenious!”

Your well-being is in your hands.

– spirometry.

A spirometry test assesses the healthy function of the respiratory system (lung function).  It is used to monitor various respiratory and pulmonary conditions (Asthma, Cystic Fibrosis, and other lung diseases),  athletic performance, or for simple preventative care.

Pulse oximetry measures the percentage of haemoglobin that carries oxygen. It is considered a vital sign like blood pressure. Oxygen levels below 95% can be a warning that urgent medical attention may be required.

– Telemedicine

View real-time test results directly on your Smartphone.  Record symptoms, take notes, save them, and share your test results with your clinician or health provider via email, WhatsApp, SMS, and more.

The Smart One pocket-size spirometer, also in its variant with pulse oximeter, Smart One OXI, and the MIR Smart One application were entirely designed and developed by MIR, MEDICAL INTERNATIONAL RESEARCH, a leading Italian company in the production of medical devices for spirometry, oximetry and telemedicine.

• Spare Turbine and Mouthpiece
• Medical quality

Write to our customer service

ITALIAN-MADE QUALITY

Thank you for contacting us.

We will get back to you as soon as possible.

Subscription successful

Thank you for signing up to our newsletter. Periodically you will receive communications on Smart One, we will keep you updated on all the news and events.

Sorry, an error has occurred.

Please try again later.

NOVYI MIR Research Journal

Ugc Care Group2 Journal || Issn No:0130-7673 || Submit Your Paper At [email protected]

Welcome To Novyi Mir Journal

Novyi Mir Research Journal is an open access scholastic and peer reviewed monthly international journal  for encouraging Researchers, Practitioners, Academicians from Life Sciences, Engineering and Technology Management sectors to contribute to their inventive Research achievements and original work to make superiority information presented for a broader civic of readers and Internet users. Novyi Mir Research Journal targets at promoting the integration of academic theories. Novyi Mir Research Journal is an open access journal, which means that all articles are available on the internet to all users immediately upon publication. Non-commercial use and distribution in any medium is permitted, provided the author and the journal are properly credited. Benefits of open access for authors include: free access for all users worldwide, authors retain copyright to their work, increased visibility and readership, rapid publication, no spatial constraints. Special issues dedicated to international conferences in the topics of the journal are brought out, as well. All submitted manuscripts are initially evaluated by the editor and, if are found suitable, are sent for further consideration, to peer reviewers for an independent and anonymous expert review process.

Submit Your Paper To  [email protected]     We Will Publish Your Paper Within 24Hrs

IMPORTANT LINKS UGC-Care Group -II Journals https://ugccare.unipune.ac.in/apps1/home/index https://mjl.clarivate.com/search-results

Submit your paper to: [email protected].

Call For Papers TOPICS Science, Engineering and Technology Arts, Social Sciences and Humanities Physical Sciences and Environment Biological & Medical Sciences Management and Commerce Agriculture and Veterinary Sciences Pharmacy Biomedical Engineering  Dental Science Integrative Medicine – viz Healthcare- viz Medical Science Architectural and design research Urban planning research Architectural and design research Architectural and design theory

Indexing Of Novyimir Research Journal

Novyimir Research Journal is indexed in more than 15 esteemed online directories followed by DOI, CROSS REF, GOOGLE SCHOLAR, CITEFACTOR, ABEC, DOAJ, LATINDEX, REDIB, CAPESSCILIT  and many more. To select the manuscripts we follow stringent guidelines to determine the originality, importance, timeliness, accessibility, grace and astonishing conclusions of the content.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings
• My Bibliography
• Collections
• Citation manager

Save citation to file

Email citation, add to collections.

• Create a new collection
• Add to an existing collection

Add to My Bibliography

Your saved search, create a file for external citation management software, your rss feed.

• Search in PubMed
• Search in NLM Catalog
• Add to Search

Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment

Affiliations.

• 1 Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya str., 8-2, 119992 Moscow, Russia.
• 2 Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechye str. 1, 115478 Moscow, Russia.
• 3 Biostatistics Department, OCT Rus, Bolshaya Moskovskaya str., 8/2, 191002 Saint-Petersburg, Russia.
• 4 Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov First Moscow State Medical University, 119435 Moscow, Russia.
• 5 Department of Pharmacology and Pharmacy, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
• 6 Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia.
• 7 Department of Biotechnology, Sirius University of Science and Technology, 1 Olympic Ave, 354340 Sochi, Russia.
• PMID: 33142700
• PMCID: PMC7712090
• DOI: 10.3390/jpm10040205

Rheumatoid arthritis (RA) is the most common autoimmune disease worldwide. Epigenetic alternations of microRNAs (miRNAs) can contribute to its pathogenesis and progression. As the first line therapy with DMARDs is not always successful, other drugs and therapeutic targets should be applied. This study aims to measure the expression level of plasma miRNAs in RA patients treated with olokizumab and to evaluate their potential as prognostic biomarkers. The expression of 9 miRNAs was quantified in 103 RA patients before treatment and at weeks 12 and 24 of olokizumab therapy by reverse transcription-polymerase chain reaction (RT-PCR) assay and analyzed in groups of responders and non-responders. Almost all miRNAs changed their expression during therapy. The ROC curve analysis of the most prominent of them together with consequent univariate and multivariate regression analysis revealed statistically significant associations with the olokizumab therapy efficiency scores for miR-26b, miR-29, miR-451, and miR-522. Therefore, these miRNAs might be a potential therapeutic response biomarker.

Keywords: biomarker; microRNA; personalized medicine; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Associations between miRNAs miR-26b, miR-29,…

Associations between miRNAs miR-26b, miR-29, miR-451, miR-522 and ARC50, DAS28. The receiver operating…

Associations of studied miRNAs with…

Associations of studied miRNAs with IL-6/IL-6R signaling pathway.

Similar articles

• Altered expression of microRNAs may predict therapeutic response in rheumatoid arthritis patients. Rezaeepoor M, Pourjafar M, Tahamoli-Roudsari A, Basiri Z, Hajilooi M, Solgi G. Rezaeepoor M, et al. Int Immunopharmacol. 2020 Jun;83:106404. doi: 10.1016/j.intimp.2020.106404. Epub 2020 Mar 18. Int Immunopharmacol. 2020. PMID: 32197230
• Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα. Castro-Villegas C, Pérez-Sánchez C, Escudero A, Filipescu I, Verdu M, Ruiz-Limón P, Aguirre MA, Jiménez-Gomez Y, Font P, Rodriguez-Ariza A, Peinado JR, Collantes-Estévez E, González-Conejero R, Martinez C, Barbarroja N, López-Pedrera C. Castro-Villegas C, et al. Arthritis Res Ther. 2015 Mar 9;17(1):49. doi: 10.1186/s13075-015-0555-z. Arthritis Res Ther. 2015. PMID: 25860297 Free PMC article.
• MicroRNAs in rheumatoid arthritis: From pathogenesis to clinical impact. Evangelatos G, Fragoulis GE, Koulouri V, Lambrou GI. Evangelatos G, et al. Autoimmun Rev. 2019 Nov;18(11):102391. doi: 10.1016/j.autrev.2019.102391. Epub 2019 Sep 11. Autoimmun Rev. 2019. PMID: 31520804 Review.
• MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis. Hruskova V, Jandova R, Vernerova L, Mann H, Pecha O, Prajzlerova K, Pavelka K, Vencovsky J, Filkova M, Senolt L. Hruskova V, et al. Arthritis Res Ther. 2016 Jun 2;18(1):124. doi: 10.1186/s13075-016-1023-0. Arthritis Res Ther. 2016. PMID: 27255643 Free PMC article.
• miRNAs as Biomarkers and Possible Therapeutic Strategies in Rheumatoid Arthritis. Kmiołek T, Paradowska-Gorycka A. Kmiołek T, et al. Cells. 2022 Jan 28;11(3):452. doi: 10.3390/cells11030452. Cells. 2022. PMID: 35159262 Free PMC article. Review.
• New Targets and Strategies for Rheumatoid Arthritis: From Signal Transduction to Epigenetic Aspect. Zhu M, Ding Q, Lin Z, Fu R, Zhang F, Li Z, Zhang M, Zhu Y. Zhu M, et al. Biomolecules. 2023 Apr 28;13(5):766. doi: 10.3390/biom13050766. Biomolecules. 2023. PMID: 37238636 Free PMC article. Review.
• Biomarkers (mRNAs and non-coding RNAs) for the diagnosis and prognosis of rheumatoid arthritis. Jiang Y, Zhong S, He S, Weng J, Liu L, Ye Y, Chen H. Jiang Y, et al. Front Immunol. 2023 Feb 1;14:1087925. doi: 10.3389/fimmu.2023.1087925. eCollection 2023. Front Immunol. 2023. PMID: 36817438 Free PMC article. Review.
• Comprehensive overview of microRNA function in rheumatoid arthritis. Peng X, Wang Q, Li W, Ge G, Peng J, Xu Y, Yang H, Bai J, Geng D. Peng X, et al. Bone Res. 2023 Jan 24;11(1):8. doi: 10.1038/s41413-023-00244-1. Bone Res. 2023. PMID: 36690624 Free PMC article. Review.
• Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis. Mikhaylenko DS, Kuznetsova EB, Musatova VV, Bure IV, Deryagina TA, Alekseeva EA, Tarasov VV, Zamyatnin AA Jr, Nemtsova MV. Mikhaylenko DS, et al. J Pers Med. 2022 Apr 15;12(4):641. doi: 10.3390/jpm12040641. J Pers Med. 2022. PMID: 35455757 Free PMC article.
• Smolen J.S., Aletaha D., McInnes I.B. Rheumatoid arthritis. Lancet. 2016;388:2023–2038. doi: 10.1016/S0140-6736(16)30173-8. - DOI - PubMed
• Wang J., Yan S., Yang J., Lu H., Xu D., Wang Z. Non-coding RNAs in Rheumatoid Arthritis: From Bench to Bedside. Front. Immunol. 2020;10:3129. doi: 10.3389/fimmu.2019.03129. - DOI - PMC - PubMed
• Gaffo A., Saag K.G., Curtis J.R. Treatment of rheumatoid arthritis. Am. J. Heal. Pharm. 2006;63:2451–2465. doi: 10.2146/ajhp050514. - DOI - PubMed
• Kim G.W., Lee N.R., Pi R.H., Lim Y.S., Lee Y.M., Lee J.M., Jeong H.S., Chung S.H. IL-6 inhibitors for treatment of rheumatoid arthritis: Past, present, and future. Arch. Pharmacal Res. 2015;38:575–584. doi: 10.1007/s12272-015-0569-8. - DOI - PubMed
• Srirangan S., Choy E.H. The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis. 2010;2:247–256. doi: 10.1177/1759720X10378372. - DOI - PMC - PubMed

Related information

Grants and funding.

• unique project ID RFMEFI60518X0003/Ministry of Education and Science of the Russian Federation

LinkOut - more resources

Full text sources.

• Europe PubMed Central
• PubMed Central

Other Literature Sources

• The Lens - Patent Citations

Research Materials

• NCI CPTC Antibody Characterization Program

• Citation Manager

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.